Chronic Pain Management: Multimodal Non-Opioid Approaches and Evidence Review

First-Line Pharmacotherapy: SNRIs and Gabapentinoids

Chronic non-cancer pain is the most common reason patients seek medical care, and it is also one of the conditions most frequently managed with therapies that either lack strong evidence or carry significant risks — opioids being the most consequential example. For the primary care physician, pain specialist, neurologist, or rheumatologist managing chronic pain, the multimodal non-opioid approach is not a compromise or a second-best strategy — it is the evidence-based standard of care that produces the best long-term outcomes when applied systematically. The key word is multimodal: no single intervention reliably controls chronic pain on its own, and the patients who do best are those receiving a combination of pharmacotherapy matched to their pain phenotype, structured physical rehabilitation, and psychological strategies that address the cognitive and emotional dimensions of persistent pain.

Duloxetine (60-120 mg daily) holds FDA approval for diabetic peripheral neuropathy, fibromyalgia, chronic musculoskeletal pain, and osteoarthritis. The NNT for 50% pain reduction is approximately 6-7 across these indications[1]. Pregabalin (150-600 mg daily in divided doses) is approved for diabetic neuropathy, postherpetic neuralgia, and fibromyalgia, with NNT of 4-8 depending on the condition[2]. Gabapentin (900-3600 mg daily in three divided doses) has comparable efficacy to pregabalin for neuropathic pain with lower cost, though its nonlinear pharmacokinetics produce less predictable dose-response relationships.

The 2023 CDC Clinical Practice Guideline for Prescribing Opioids recommends these agents as first-line therapy for neuropathic and nociplastic pain conditions. Combination therapy (SNRI plus gabapentinoid) may provide additive benefit through complementary mechanisms, though the COMBO-DN trial in diabetic neuropathy showed only modest improvement with high-dose combination versus optimized monotherapy.

Topical Agents: Targeted Analgesia

Topical agents minimize systemic exposure while providing local analgesia. Diclofenac gel 1% (NNT 6.4 for knee OA)[3] and topical NSAIDs are recommended by ACR/OARSI guidelines for knee and hand osteoarthritis. Lidocaine 5% patches provide localized relief for postherpetic neuralgia (NNT 4.4). Capsaicin 8% patches (Qutenza) offer 3-month pain reduction after a single 60-minute application for peripheral neuropathic pain, with NNT of 8-12. Compounded topical formulations (ketamine/amitriptyline/baclofen combinations) lack rigorous RCT support but are used in refractory cases.

Interventional Approaches

Epidural steroid injections provide short-term (2-6 weeks) relief for lumbar radiculopathy but lack evidence for long-term benefit or avoidance of surgery. Radiofrequency ablation of medial branch nerves offers 6-12 months of relief for facet-mediated pain, with responder rates of 50-70% in properly selected patients confirmed by diagnostic medial branch blocks. Spinal cord stimulation has evolved with high-frequency (10 kHz, SENZA-RCT data) and dorsal root ganglion stimulation modalities, showing sustained pain reduction of 50-70% in CRPS and failed back surgery syndrome[4].

Selecting Interventional Procedures: Who Benefits?

The value of interventional pain procedures depends heavily on patient selection. Epidural steroid injections are most useful as a bridge — providing temporary relief that allows a patient to participate in physical therapy during an acute radiculopathy flare, not as a long-term management strategy on a recurring schedule. Radiofrequency ablation requires proper diagnostic confirmation with medial branch blocks before proceeding to the therapeutic procedure; performing ablation without positive diagnostic blocks yields unpredictable results. Spinal cord stimulation is reserved for patients who have failed conservative management and are not surgical candidates, and a successful trial stimulation period is mandatory before permanent implantation. The common thread is that interventional approaches work best when they are targeted to the right patient at the right point in their treatment trajectory, not offered reflexively when medications have not fully resolved symptoms.